Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.

Molecular cancer therapeutics - 1 Sept 2012

Dienstmann Rodrigo, Serpico Danila, Rodon Jordi, Saura Cristina, Macarulla Teresa, Elez Elena, Alsina Maria, Capdevila Jaume, Perez-Garcia Jose, Sánchez-Ollé Gessamí, Aura Claudia, Prudkin Ludmila, Landolfi Stefania, Hernández-Losa Javier, Vivancos Ana, Tabernero Josep

Abstract excerpt

Clinical experience increasingly suggests that molecular prescreening and biomarker enrichment strategies in phase I trials with targeted therapies will improve the outcomes of patients with cancer. In keeping with the exigencies of a personalized oncology program, tumors from patients with advanced chemorefractory colorectal cancer were analyzed for specific aberrations (KRAS/BRAF/PIK3CA mutations, PTEN and pMET...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to Clinical Trials, Phase I as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Patient Selection

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-met

Share to PTEN Phosphohydrolase

Share to ras Proteins

Source

Identifiers

PMID: 22723336
DOI: 10.1158/1535-7163.MCT-12-0290

Genes

BRAF
KRAS
PTEN
EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.PMID 22723336Read ↗

Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.Semantic proximity Read ↗

EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.Semantic proximity Read ↗

Targeted therapies in colorectal cancer—an integrative view by PPPMSemantic proximity Read ↗

Cell line models for drug discovery in PIK3CA-mutated colorectal cancers.Semantic proximity Read ↗

Evaluating Patient-Derived Colorectal Cancer Xenografts as Preclinical Models by Comparison with Patient Clinical DataSemantic proximity Read ↗

KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.Semantic proximity Read ↗

KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.Semantic proximity Read ↗

Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study.Semantic proximity Read ↗

Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.Semantic proximity Read ↗

Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer TreatmentSemantic proximity Read ↗

The Patient Journey and Guideline Concordant Care in Colorectal Cancer – Is Current Practice Enough?Semantic proximity Read ↗

Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.